Tags

Type your tag names separated by a space and hit enter

[The assessment of cynacalcet (Mimpara) accompanied by alfacalcidol treatment efficacy in haemodialysis patients with different secondary hyperparathyroidism severity recognized by iPTH].
Wiad Lek. 2011; 64(4):267-73.WL

Abstract

INTRODUCTION

Calcimimetics are highly efficient drugs in treatment of secondary hyperparathyroidism (sHPT) in patients on haemodialysis. The effect and the dose of cinacalcet may depend on severity of sHPT, and alfacalcidol supplementation helps in the treatment optimization. The study evaluated cinacalcet and alfacalcidol treatment efficacy in haemodialysis patients with different secondary hyperparathyroidism severity recognized by iPTH.

MATERIAL AND METHODS

The study group comprised of 82 participants (male 67 and 34 female) in aged from 36 to 75 years, on haemodialysis. All patients were divided into two groups: the study group--40 participants treated with cinacalcet accompanied by alfacalcidol started after 8 months of the study (0.25 to 0.5 microg/day) and the control group--42 patients. The study group comprises of two subgroups: I--moderate sHPT with iPTH 500 to 800 pg/ml and II--severe sHPT with iPTH > 800 pg/ml. The basic phosphate binder treatment throughout the study period in all groups was calcium carbonate.

RESULTS

In the subgroup I initial mean iPTH 700 +/- 129 pg/ml was reduced to 550 +/- 61 pg/ml (p < 0.05) in the third month with no need of the Mimpara dose change. No further iPTH decrease up to eighth month of the treatment was observed despite the cinacalcet dose increase to 53 mg (p < 0.05). The alfacalcidol supplementation decreased iPTH to 331 +/-55 pg/ml (p < 0.05) and the cynacalcet dose to 42 mg (p < 0.05). In the II subgroup iPTH was reduced from 1035 +/- 149 pg/ml to 885 +/- 101 pg/ml (p < 0.05) in the third month of the treatment and Mimpara dose changed to 90 mg. Up to eighth month iPTH did not change (790 +/- 92 pg/ml; p > 0.05) despite the cinacalcet dose increase to 122 mg (p < 0.05). The alfacalcidol supplementation induced iPTH reduction to 622 +/- 71 pg/ml (p < 0.05) and the cinacalcet dose to 100 mg (p < 0.05).

CONCLUSIONS

Cinacalcet convinced its effectiveness in the iPTH serum concentration control in haemodialysis patients independently of secondary hyperparathyroidism severity and alfacalcidol supplementation enhanced its efficacy. Still in case of the late introduction of Mimpara this drug was recognized as potent however the efficient dose was mandatory multiply.

Authors+Show Affiliations

Zakład Transplantologii Nerek, Uniwersytet Medyczny w Łodzi, Stacja Dializ, Uniwersytecki Szpital Kliniczny Nr 1 im. N. Barlickiego w Łodzi. rzwiech@mp.plNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Controlled Clinical Trial
Journal Article

Language

pol

PubMed ID

22533150

Citation

Zwiech, Rafał, et al. "[The Assessment of Cynacalcet (Mimpara) Accompanied By Alfacalcidol Treatment Efficacy in Haemodialysis Patients With Different Secondary Hyperparathyroidism Severity Recognized By IPTH]." Wiadomosci Lekarskie (Warsaw, Poland : 1960), vol. 64, no. 4, 2011, pp. 267-73.
Zwiech R, Dryja P, Łacina D, et al. [The assessment of cynacalcet (Mimpara) accompanied by alfacalcidol treatment efficacy in haemodialysis patients with different secondary hyperparathyroidism severity recognized by iPTH]. Wiad Lek. 2011;64(4):267-73.
Zwiech, R., Dryja, P., Łacina, D., Nykiel, P., Sek-Szczepanowska, K., Bratkowska, K., Pietrzak, B., & Chrul, S. (2011). [The assessment of cynacalcet (Mimpara) accompanied by alfacalcidol treatment efficacy in haemodialysis patients with different secondary hyperparathyroidism severity recognized by iPTH]. Wiadomosci Lekarskie (Warsaw, Poland : 1960), 64(4), 267-73.
Zwiech R, et al. [The Assessment of Cynacalcet (Mimpara) Accompanied By Alfacalcidol Treatment Efficacy in Haemodialysis Patients With Different Secondary Hyperparathyroidism Severity Recognized By IPTH]. Wiad Lek. 2011;64(4):267-73. PubMed PMID: 22533150.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [The assessment of cynacalcet (Mimpara) accompanied by alfacalcidol treatment efficacy in haemodialysis patients with different secondary hyperparathyroidism severity recognized by iPTH]. AU - Zwiech,Rafał, AU - Dryja,Przemysław, AU - Łacina,Dominik, AU - Nykiel,Paweł, AU - Sek-Szczepanowska,Karolina, AU - Bratkowska,Katarzyna, AU - Pietrzak,Beata, AU - Chrul,Sławomir, PY - 2012/4/27/entrez PY - 2011/1/1/pubmed PY - 2012/5/30/medline SP - 267 EP - 73 JF - Wiadomosci lekarskie (Warsaw, Poland : 1960) JO - Wiad Lek VL - 64 IS - 4 N2 - INTRODUCTION: Calcimimetics are highly efficient drugs in treatment of secondary hyperparathyroidism (sHPT) in patients on haemodialysis. The effect and the dose of cinacalcet may depend on severity of sHPT, and alfacalcidol supplementation helps in the treatment optimization. The study evaluated cinacalcet and alfacalcidol treatment efficacy in haemodialysis patients with different secondary hyperparathyroidism severity recognized by iPTH. MATERIAL AND METHODS: The study group comprised of 82 participants (male 67 and 34 female) in aged from 36 to 75 years, on haemodialysis. All patients were divided into two groups: the study group--40 participants treated with cinacalcet accompanied by alfacalcidol started after 8 months of the study (0.25 to 0.5 microg/day) and the control group--42 patients. The study group comprises of two subgroups: I--moderate sHPT with iPTH 500 to 800 pg/ml and II--severe sHPT with iPTH > 800 pg/ml. The basic phosphate binder treatment throughout the study period in all groups was calcium carbonate. RESULTS: In the subgroup I initial mean iPTH 700 +/- 129 pg/ml was reduced to 550 +/- 61 pg/ml (p < 0.05) in the third month with no need of the Mimpara dose change. No further iPTH decrease up to eighth month of the treatment was observed despite the cinacalcet dose increase to 53 mg (p < 0.05). The alfacalcidol supplementation decreased iPTH to 331 +/-55 pg/ml (p < 0.05) and the cynacalcet dose to 42 mg (p < 0.05). In the II subgroup iPTH was reduced from 1035 +/- 149 pg/ml to 885 +/- 101 pg/ml (p < 0.05) in the third month of the treatment and Mimpara dose changed to 90 mg. Up to eighth month iPTH did not change (790 +/- 92 pg/ml; p > 0.05) despite the cinacalcet dose increase to 122 mg (p < 0.05). The alfacalcidol supplementation induced iPTH reduction to 622 +/- 71 pg/ml (p < 0.05) and the cinacalcet dose to 100 mg (p < 0.05). CONCLUSIONS: Cinacalcet convinced its effectiveness in the iPTH serum concentration control in haemodialysis patients independently of secondary hyperparathyroidism severity and alfacalcidol supplementation enhanced its efficacy. Still in case of the late introduction of Mimpara this drug was recognized as potent however the efficient dose was mandatory multiply. SN - 0043-5147 UR - https://wwww.unboundmedicine.com/medline/citation/22533150/[The_assessment_of_cynacalcet__Mimpara__accompanied_by_alfacalcidol_treatment_efficacy_in_haemodialysis_patients_with_different_secondary_hyperparathyroidism_severity_recognized_by_iPTH]_ L2 - https://medlineplus.gov/dialysis.html DB - PRIME DP - Unbound Medicine ER -